向日葵：子公司贝得药业部分产品拟中选国家组织集采药品协议期满品种接续采购

Core Viewpoint - The company Sunflower announced that its subsidiary, Beid Pharmaceutical, is participating in the continuation procurement of drugs from the national organized procurement batches 1-8, with some products expected to be selected [1] Group 1: Selected Products - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets [1] - The procurement period for the selected products will last from the actual execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The sales revenue for Clarithromycin tablets in 2024 is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue for Simvastatin tablets is expected to be 1.71 million yuan, representing 0.52% of the company's main business income for the same period [1]